Skip to main content
. 2021 Jan 4;118(2):e2008815118. doi: 10.1073/pnas.2008815118

Fig. 1.

Fig. 1.

Validation of the split-GFP–Prp8 intein-splicing assay. (A) The Prp8 intein-splicing assay based on split-GFP. GFP (200 nM) and GFP–Prp8i (200 nM) were used with DMF or cisplatin (40 µM) for fluorescence detection. n = 8. ***P < 0.001. (B) Dose–response fitting of inhibition of splicing of the GFP–Prp8i by cisplatin. GFP–Prp8i (200 nM) was used. Cisplatin was in twofold serial dilutions with concentrations ranging from 100 µM (30 µg/mL) to 0.78 µM (0.23 µg/mL). n = 3.